Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent BioBlast® Updates

Approval Alert: Novo Nordisk’s Wegovy® Approved in China

Jun 26, 2024

Novo Nordisk announced that Wegovy® has been approved in China for long-term weight management, targeting patients with a BMI of 30kg/m² and at least one weight-related comorbidity.    The approval comes as the company plans a $4.1 billion expansion of its US...

Simcere Zaiming Cetuximab Beta Approved In China

Jun 26, 2024

On 25 June 2024, Simcere Zaiming announced the approval of Enlituo® (cetuximab beta) in the PRC for use in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC). The drug was developed in...

Approval Alert: Biogen’s Tocilizumab Biosimilar EU Approved

Jun 24, 2024

On 24 June 2024, Biogen announced its IV tocilizumab, TOFIDENCE™, biosimilar to Roche’s ROACTEMRA®, has been approved by EC.  Tofidence is authorised by the EC for treating moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis,...

Teva Announces US Launch of Authorised Generic Liraglutide

Jun 24, 2024

On 24 June 2024, Teva Pharmaceuticals announced the US launch of its authorised generic liraglutide injection (1.8 mg) for type 2 diabetes.  Originator Novo Nordisk supplies liraglutide as Victoza®, and Teva’s authorised generic Victoza is the first generic GLP-1...

Phase 3 Results for Qilu Pharmaceutical’s Pertuzumab Biosimilar

Jun 21, 2024

Results of phase 3 pertuzumab studies comparing Qilu’s QL1209 with Roche’s Perjeta® with trastuzumab and docetaxel were published in the British Journal of Cancer on 21 June 2024.   The studies demonstrated that QL1209 is equivalent to Perjeta® in safety and efficacy...

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here